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due to early or late starters in the database. Main
outcome: proportion of patients adhered to antidepres-
sant medication therapy recommended by the AHCPR.
RESULTS: A total of 5105 patients were included in the
study. The average days of therapy was 140 days, persis-
tence over time was 75%, 70%, 65%, 63%, 54%, and
50% at month 2, 3, 4, 5, 6, and 7 respectively. These
results indicated 70% of patients adhered to their anti-
depressant drug regimen during the acute phase of
therapy and 50% complied with therapy during the con-
tinuation phase. The possession ratio analysis demon-
strated that patients only obtained 54% of the expected
number of doses at 6 months. This was supported by the
median gap (11.78 days) analysis that patients typically
had prescriptions reﬁlled at less than half the expected
frequency. Adherence outcomes were similar in patients
who received tricyclic antidepressants when compared 
to patients who received selective serotonin reuptake
inhibitors during acute phase, 68% vs. 70% (p = 0.18)
and during continuation phase, 50% vs. 52% (p = 0.23).
CONCLUSIONS: Our study showed that many patients
ceased medication use at an earlier than expected rate,
especially during the ﬁrst 3 months of therapy.
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OBJECTIVE: Evaluate the diagnoses recorded for
patients prescribed atypical antipsychotic (AAP) agents
by demographic and medication variables. METHODS:
Information for adult Texas Medicaid patients who 
commenced AAP therapy between 1999 and 2001 was
extracted from prescription and medical claims. Patients
were stratiﬁed according to the following hierarchy of
mutually exclusive diagnostic categories—schizophrenia,
bipolar disorder, other psychotic/delusional disorders,
and other diagnoses. RESULTS: Data were available for
11,209 patients (6,482 < 65 and 4,727 >= 65 years old).
Distributions of diagnoses varied according to age.
Overall, 19% of patients had a diagnosis for schizophre-
nia (28% for < 65 years, 5% for >= 65 years), 28% for
bipolar disorder (31% < 65, 22% for >= 65 years), and
22% for other psychotic/delusional disorders (11% < 65,
37% >= 65). For patients < 65 there were signiﬁcant dif-
ferences in coded diagnoses by gender and race; for those
over 65, differences were only seen for race categories.
For patients with a diagnosis of schizophrenia, a higher
percent were initiated on olanzapine (33% < 65, 6% >=
65). For patients with a diagnosis of bipolar disorder, a
higher percent were initiated on quetiapine (41% < 65,
28% >= 65). For patients with a diagnosis of other psy-
chotic/delusional disorders, a higher percent of patients
were initiated on risperidone (13% < 65, 38% >= 65).
For all medications and diagnoses, mean daily doses for
patients < 65 were about double the mean doses for those
>= 65. For both age groups, the mean daily dose for each
medication was 40 to 80 percent higher for patients with
a diagnosis of schizophrenia compared to patients with
other diagnoses. CONCLUSIONS: Results indicate that
AAP medications were prescribed for a diverse range of
indications. The dose of AAP prescribed varied signiﬁ-
cantly according to treatment indication and patient age.
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Atypical antipsychotics (AAPs) are the cornerstone of
therapy for schizophrenia based on their effective man-
agement of positive and negative symptoms. Clinical
success is limited by partial compliance resulting in
relapses. While conventional depot antipsychotics guar-
antee the delivery of medication the lack of a long-acting
AAP has limited treatment options. OBJECTIVE: The
purpose of this analysis was to examine outcomes for
patients treated with the ﬁrst long-acting AAP in Canada.
METHODS: CNOMSS is an ongoing prospective, longi-
tudinal, population-based epidemiological study involv-
ing 457 patients at 32 community and academic sites
across Canada. Demographic and clinical data are col-
lected for patients treated with antipsychotic medications
under the conditions of routine clinical practice. This
exploratory analysis included 21 patients treated with
Risperdal Consta who completed at least 1 year of follow-
up. RESULTS: While the majority (57.1%) of patients
were considered “Mild” according to the Clinical Global
Impression Rating Scale (CGI), signiﬁcant improvement
was seen over 2 years of observation (p = 0.033). Simi-
larly, while most (47.6%) patients entered at baseline as
“Much Improved” since their last visit prior to entry (CGI
Improvement Rating Scale), they demonstrated improve-
ment compared to baseline in both the ﬁrst (p = 0.002)
and second year (p = 0.007) of treatment. The Brief 
Psychiatric Rating Scale (BPRS) also demonstrated
improvement over the ﬁrst (p < 0.001) and second (p =
0.056) years of observation. While observational data 
is often exposed to selection bias, it is also a rich source
of long-term outcomes for new therapies. Here we
examine a small sample of patients treated with 
Risperdal Consta that demonstrate continued long-term
improvement with this novel agent. CONCLUSION:
The addition of a long-acting AAP to the psychiatrist’s 
armamentarium has the potential to substantially
improve outcomes in persons with schizophrenia in
Canada.
